Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study

Conditions

• Prurigo Nodularis

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Dupilumab — DRUG
  Injection solution; subcutaneous

Study Details

This study is a prospective, multinational, observational investigation designed to elucidate the real-world effectiveness and treatment patterns of dupilumab therapy in adult patients diagnosed with prurigo nodularis (PN). The primary objective of this study is to comprehensively characterize the real-world usage of dupilumab for the management of PN. In addition to this, the study aims to achieve several secondary objectives, including a detailed assessment of the medical history, socio-demographic and disease characteristics of dupilumab-treated PN patients, as well as the evaluation of the long-term real-world effectiveness of dupilumab therapy for PN.

Key Dates

Start date

Dec 12, 2023

Status verified

Sep 2025

Primary completion

Sep 22, 2026

Completion

Sep 22, 2026

Study Design

Enrollment

100 participants (estimated)

Arms

• Arm: Patient with prurigo nodularis
  Participants aged 18 years or older who start receiving dupilumab for prurigo nodularis (according to the country-specific prescribing information) prior to and independently of their participation in the study

Primary Outcome Measure

Frequency of reasons for dupilumab treatment initiation with the description of dosing, frequency and duration of treatment [ Time Frame: At baseline ]

Locations (23)

Find similar trials in Phoenix, AZ

Related Studies

• A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
  PHASE3 · Recruiting · Sanofi · Palo Alto, California
• Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults
  Recruiting · Galderma R&D · Birmingham, Alabama